HomeAI · summaries
Storia in 3 fonti
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the prevention setting.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Xocova for COVID-19 prevention after exposure
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to someone with the disease, according to the drug’s…
- ·
fiercepharma.com
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a prior misfire in demonstrating its protease…
